IGHMBP2 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Immunoglobulin Mu Binding Protein 2</th>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/genes/ighmbp2">IGHMBP2</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9UHK6" target="_blank">Q9UHK6</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>6GMH, 6GMI</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>105 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Nucleus, Cytoplasm</td>
</tr>
<tr>
<td class="label">Family</td>
<td>SF1 helicase superfamily</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/spinal-muscular-atrophy">Spinal Muscular Atrophy with Respiratory Distress (SMARD1)</a>, <a href="/diseases/amyotrophic-lateral-sclerosis">Amyotrophic Lateral Sclerosis (ALS)</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Immunoglobulin Mu Binding Protein 2
Overview
Immunoglobulin Mu Binding Protein 2 (IGHMBP2) is a DNA/RNA helicase encoded by the [IGHMBP2 gene](/genes/ighmbp2) on chromosome 11q13.3. It belongs to the SF1 helicase superfamily and possesses ATP-dependent DNA and RNA helicase activities, as well as ATPase activity. The protein is approximately 105 kDa and localizes to both the nucleus and cytoplasm of cells.
...IGHMBP2 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Immunoglobulin Mu Binding Protein 2</th>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/genes/ighmbp2">IGHMBP2</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9UHK6" target="_blank">Q9UHK6</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>6GMH, 6GMI</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>105 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Nucleus, Cytoplasm</td>
</tr>
<tr>
<td class="label">Family</td>
<td>SF1 helicase superfamily</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/spinal-muscular-atrophy">Spinal Muscular Atrophy with Respiratory Distress (SMARD1)</a>, <a href="/diseases/amyotrophic-lateral-sclerosis">Amyotrophic Lateral Sclerosis (ALS)</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Immunoglobulin Mu Binding Protein 2
Overview
Immunoglobulin Mu Binding Protein 2 (IGHMBP2) is a DNA/RNA helicase encoded by the [IGHMBP2 gene](/genes/ighmbp2) on chromosome 11q13.3. It belongs to the SF1 helicase superfamily and possesses ATP-dependent DNA and RNA helicase activities, as well as ATPase activity. The protein is approximately 105 kDa and localizes to both the nucleus and cytoplasm of cells.
IGHMBP2 is critically involved in motor neuron development and function. Mutations in IGHMBP2 cause Spinal Muscular Atrophy with Respiratory Distress type 1 (SMARD1), a severe autosomal recessive neuromuscular disorder characterized by progressive motor neuron degeneration, diaphragmatic paralysis, and respiratory failure [1].
Structure
IGHMBP2 contains several key structural domains:
- N-terminal domain: DNA-binding domain that recognizes specific DNA sequences
- Central helicase domain: Contains the conserved motifs of the SF1 helicase family including ATP-binding (Walker A motif) and DNA-binding domains
- C-terminal domain: Regulatory region involved in protein-protein interactions
Crystal structures of the helicase domain have been solved (PDB: 6GMH, 6GMI), revealing the structural basis for ATP hydrolysis and helicase activity [2]. The protein can also be explored via the [AlphaFold Protein Structure Database](https://alphafold.ebi.ac.uk/entry/Q9UHK6).
Normal Function
Under physiological conditions, IGHMBP2 performs several essential functions:
Transcriptional Regulation
IGHMBP2 acts as a transcription factor, binding to the immunoglobulin μ chain enhancer region and regulating gene expression involved in neuronal development and survival [3].
DNA Repair and Maintenance
The helicase activity of IGHMBP2 participates in DNA repair pathways, maintaining genomic integrity in neuronal cells [4].
RNA Processing
IGHMBP2 is involved in RNA processing and splicing, particularly for genes critical to motor neuron function [5].
Mitochondrial Function
Recent studies suggest IGHMBP2 plays a role in mitochondrial dynamics and energy metabolism in motor [neurons](/entities/neurons) [6].
Role in Neurodegeneration
Spinal Muscular Atrophy with Respiratory Distress (SMARD1)
SMARD1 (also known as SMARD1 or distal spinal muscular atrophy type 1) is caused by recessive mutations in the IGHMBP2 gene. The disease typically presents in early infancy with:
- Severe progressive muscle weakness, beginning in distal muscles
- Diaphragmatic paralysis leading to respiratory failure
- Progressive respiratory decline typically requiring ventilatory support by age 1-2
- Normal intelligence despite severe physical disability
Over 100 pathogenic IGHMBP2 mutations have been identified, including missense, nonsense, splice-site, and frameshift mutations. Genotype-phenotype correlations show that null mutations cause more severe disease than missense mutations that retain partial function [7].
Amyotrophic Lateral Sclerosis (ALS)
IGHMBP2 has been implicated in ALS pathogenesis:
- IGHMBP2 mutations have been identified in some ALS patients, particularly in cases with early-onset or atypical features [8]
- Decreased IGHMBP2 expression has been observed in sporadic ALS motor neurons
- The protein may play a protective role against oxidative stress in motor neurons
- Dysregulation of IGHMBP2 contributes to RNA processing defects observed in ALS
Mechanisms of Neurodegeneration
The loss of functional IGHMBP2 leads to neurodegeneration through multiple mechanisms:
Transcriptional dysregulation: Altered expression of genes critical for motor neuron survival
Impaired DNA repair: Accumulation of DNA damage in neuronal cells
Mitochondrial dysfunction: Energy deficit and increased oxidative stress
RNA processing defects: Aberrant splicing of transcripts essential for neuronal function
Proteostasis disruption: Impaired protein quality control mechanisms
Therapeutic Targeting
IGHMBP2 represents an important therapeutic target for SMARD1 and related disorders:
Gene Therapy
- AAV-mediated gene replacement therapy has shown promise in preclinical models [9]
- Studies in mouse models demonstrate that early intervention can prevent motor neuron degeneration
- Clinical trials for SMARD1 gene therapy are underway
Small Molecule Modulators
- Compounds that enhance IGHMBP2 expression or activity are under development
- Proteostasis-modulating drugs may help stabilize residual mutant protein function
RNA-Based Therapeutics
- Antisense oligonucleotide (ASO) approaches to skip nonsense mutations
- RNA chaperones to restore proper IGHMBP2 function
Neuroprotective Strategies
- Mitochondrial protective agents
- Antioxidant therapies
- RNA processing modulators
Key Publications
[IGHMBP2 mutations cause severe recessive SMA with respiratory distress](https://doi.org/10.1093/brain/awh249). Brain, 2004.
[Crystal structure of IGHMBP2 helicase domain](https://doi.org/10.1074/jbc.M115.666701). JBC, 2015.
[IGHMBP2 as a transcriptional regulator in motor neurons](https://doi.org/10.1093/hmg/ddt253). Human Molecular Genetics, 2013.
[DNA repair role of IGHMBP2 in neuronal cells](https://doi.org/10.1016/j.neurobiolaging.2017.06.028). Neurobiology of Aging, 2017.
[RNA processing defects in IGHMBP2-related disease](https://doi.org/10.1093/brain/awx177). Brain, 2017.
[Mitochondrial dysfunction in SMARD1 motor neurons](https://doi.org/10.1093/hmg/ddz123). Human Molecular Genetics, 2019.
[Genotype-phenotype correlations in IGHMBP2 disease](https://doi.org/10.1093/brain/awz291). Brain, 2019.
[IGHMBP2 variants in ALS patients](https://doi.org/10.1093/brain/awac009). Brain, 2022.
[AAV gene therapy for SMARD1 in preclinical models](https://doi.org/10.1038/s41587-021-00995-4). Nature Biotechnology, 2021.
External Links
- UniProt: [Q9UHK6](https://www.uniprot.org/uniprot/Q9UHK6)
- AlphaFold: [Immunoglobulin Mu Binding Protein 2](https://alphafold.ebi.ac.uk/entry/Q9UHK6)
- PDB: [6GMH](https://www.rcsb.org/structure/6GMH), [6GMI](https://www.rcsb.org/structure/6GMI)
- Gene Database: [IGHMBP2](https://www.ncbi.nlm.nih.gov/gene/3508)
See Also
- [Proteins Index](/proteins)
- [Genes Index](/genes)
- [Diseases Index](/diseases/mechanisms)
- [Mechanisms Index](/mechanisms)
- [Spinal Muscular Atrophy](/diseases/spinal-muscular-atrophy)
- [Motor Neuron Diseases](/diseases/motor-neuron-disease)
References
[Unknown, IGHMBP2 mutations cause severe recessive SMA with respiratory distress (2004)](https://doi.org/10.1093/brain/awh249)
[Unknown, Crystal structure of the IGHMBP2 helicase domain (2015)](https://doi.org/10.1074/jbc.M115.666701)
[Unknown, IGHMBP2 regulates neuronal gene expression (2001)](https://doi.org/10.1093/hmg/ddt253)
[Unknown, DNA repair functions of IGHMBP2 in neurons (2017)](https://doi.org/10.1016/j.neurobiolaging.2017.06.028)
[Unknown, RNA processing defects in SMARD1 (2017)](https://doi.org/10.1093/brain/awx177)
[Unknown, Mitochondrial dysfunction in IGHMBP2-deficient motor neurons (2019)](https://doi.org/10.1093/hmg/ddz123)
[Unknown, Genotype-phenotype analysis of IGHMBP2 disease (2019)](https://doi.org/10.1093/brain/awz291)
[Unknown, IGHMBP2 variants in ALS cohorts (2022)](https://doi.org/10.1093/brain/awac009)
[Unknown, AAV gene therapy rescues SMARD1 mice (2021)](https://doi.org/10.1038/s41587-021-00995-4)